What Researchers Did
Researchers conducted a pilot clinical trial evaluating radiotherapy for glioblastoma with (38 patients) or without (42 control patients) hyperbaric oxygen.
What They Found
At 18 months, the hyperbaric oxygen group showed a considerably higher survival rate (28%) compared to controls (10%). The median survival time was 38 weeks for the oxygen group versus 31 weeks for the air control group, with 2 oxygen patients surviving beyond 45 and 48 months while no controls survived past 36 months. However, due to small sample sizes, this difference was not statistically significant.
What This Means for Canadian Patients
This pilot study suggests that hyperbaric oxygen combined with radiotherapy might improve survival for glioblastoma patients, but these findings require confirmation from larger, definitive trials. Canadian patients should discuss current standard treatments with their oncologists, as hyperbaric oxygen is not yet a proven or standard therapy for glioblastoma.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The small sample size and pilot nature of this study meant that the observed differences in survival rates were not statistically significant.